![[Video] The Weekly Break Out Ep. 19: Army aviation’s shakeup and the F-35’s future](https://breakingdefense.com/wp-content/uploads/sites/3/2025/05/EP-19-THUMB-play-button.jpg?#)
FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset
The FDA has slapped Savara with a refuse to file letter after the biotech in March applied for approval of its inhaled respiratory disease candidate molgramostim in autoimmune pulmonary alveolar proteinosis.
The FDA has slapped Savara with a refuse to file letter after the biotech in March applied for approval of its inhaled respiratory disease candidate molgramostim in autoimmune pulmonary alveolar proteinosis.
